Literature DB >> 22628437

Blocking toll-like receptors 7 and 9 reduces postinterventional remodeling via reduced macrophage activation, foam cell formation, and migration.

Jacco C Karper1, Mark M Ewing, Kim L L Habets, Margreet R de Vries, Erna A B Peters, Annemarie M van Oeveren-Rietdijk, Hetty C de Boer, Jaap F Hamming, Johan Kuiper, Ekambar R Kandimalla, Nicola La Monica, J Wouter Jukema, Paul H A Quax.   

Abstract

OBJECTIVE: The role of toll-like receptors (TLRs) in vascular remodeling is well established. However, the involvement of the endosomal TLRs is unknown. Here, we study the effect of combined blocking of TLR7 and TLR9 on postinterventional remodeling and accelerated atherosclerosis. METHODS AND
RESULTS: In hypercholesterolemic apolipoprotein E*3-Leiden mice, femoral artery cuff placement led to strong increase of TLR7 and TLR9 presence demonstrated by immunohistochemistry. Blocking TLR7/9 with a dual antagonist in vivo reduced neointimal thickening and foam cell accumulation 14 days after surgery by 65.6% (P=0.0079). Intima/media ratio was reduced by 64.5% and luminal stenosis by 62.8%. The TLR7/9 antagonist reduced the arterial wall inflammation, with reduced macrophage infiltration, decreased cytoplasmic high-mobility group box 1 expression, and altered serum interleukin-10 levels. Stimulation of cultured macrophages with TLR7 and TLR9 ligands enhanced tumor necrosis factor-α expression, which is decreased by TLR7/9 antagonist coadministration. Additionally, the antagonist abolished the TLR7/9-enhanced low-density lipoprotein uptake. The antagonist also reduced oxidized low-density lipoprotein-induced foam cell formation, most likely not via decreased influx but via increased efflux, because CD36 expression was unchanged whereas interleukin-10 levels were higher (36.1 ± 22.3 pg/mL versus 128.9 ± 6.6 pg/mL; P=0.008).
CONCLUSIONS: Blocking TLR7 and TLR9 reduced postinterventional vascular remodeling and foam cell accumulation indicating TLR7 and TLR9 as novel therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22628437     DOI: 10.1161/ATVBAHA.112.249391

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  12 in total

1.  HMGB1-Driven Inflammation and Intimal Hyperplasia After Arterial Injury Involves Cell-Specific Actions Mediated by TLR4.

Authors:  Jingjing Cai; Hong Yuan; Qingde Wang; Huan Yang; Yousef Al-Abed; Zhong Hua; Jiemei Wang; Dandan Chen; Jinze Wu; Ben Lu; John P Pribis; Weihong Jiang; Kan Yang; David J Hackam; Kevin J Tracey; Timothy R Billiar; Alex F Chen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-10-29       Impact factor: 8.311

Review 2.  Inflammation-induced foam cell formation in chronic inflammatory disease.

Authors:  Thomas A Angelovich; Anna C Hearps; Anthony Jaworowski
Journal:  Immunol Cell Biol       Date:  2015-03-10       Impact factor: 5.126

Review 3.  The Role of Toll-like Receptors in Atherothrombotic Cardiovascular Disease.

Authors:  Ying Zhou; Peter J Little; Liam Downey; Rizwana Afroz; Yuao Wu; Hang T Ta; Suowen Xu; Danielle Kamato
Journal:  ACS Pharmacol Transl Sci       Date:  2020-02-06

Review 4.  Toll-like Receptors in the Vascular System: Sensing the Dangers Within.

Authors:  Styliani Goulopoulou; Cameron G McCarthy; R Clinton Webb
Journal:  Pharmacol Rev       Date:  2016-01       Impact factor: 25.468

5.  Proinflammatory Stimulation of Toll-Like Receptor 9 with High Dose CpG ODN 1826 Impairs Endothelial Regeneration and Promotes Atherosclerosis in Mice.

Authors:  Alexander O Krogmann; Enzo Lüsebrink; Martin Steinmetz; Tobias Asdonk; Catharina Lahrmann; Dieter Lütjohann; Georg Nickenig; Sebastian Zimmer
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

6.  Toll-like receptor 7 deficiency protects apolipoprotein E-deficient mice from diet-induced atherosclerosis.

Authors:  Cong-Lin Liu; Marcela M Santos; Cleverson Fernandes; Mengyang Liao; Karine Iamarene; Jin-Ying Zhang; Galina K Sukhova; Guo-Ping Shi
Journal:  Sci Rep       Date:  2017-04-12       Impact factor: 4.379

7.  TLR9 Deficiency in B Cells Promotes Immune Tolerance via Interleukin-10 in a Type 1 Diabetes Mouse Model.

Authors:  Sha Sha; James A Pearson; Jian Peng; Youjia Hu; Juan Huang; Yanpeng Xing; Luyao Zhang; Ying Zhu; Hongyu Zhao; F Susan Wong; Li Chen; Li Wen
Journal:  Diabetes       Date:  2020-11-05       Impact factor: 9.461

8.  Electronic Cigarettes Induce Mitochondrial DNA Damage and Trigger TLR9 (Toll-Like Receptor 9)-Mediated Atherosclerosis.

Authors:  Jieliang Li; Luong Huynh; William D Cornwell; Moon-Shong Tang; Hannah Simborio; Jing Huang; Beata Kosmider; Thomas J Rogers; Huaqing Zhao; Michael B Steinberg; Le Thu Thi Le; Lanjing Zhang; Kien Pham; Chen Liu; He Wang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-12-31       Impact factor: 10.514

9.  Toll-Like Receptor 9 Inactivation Alleviated Atherosclerotic Progression and Inhibited Macrophage Polarized to M1 Phenotype in ApoE-/- Mice.

Authors:  Chunmei Ma; Qiufang Ouyang; Ziyang Huang; Xiaoqing Chen; Ye Lin; Weiping Hu; Ling Lin
Journal:  Dis Markers       Date:  2015-07-15       Impact factor: 3.434

10.  Deficiency of TLR4 homologue RP105 aggravates outward remodeling in a murine model of arteriovenous fistula failure.

Authors:  Taisiya Bezhaeva; ChunYu Wong; Margreet R de Vries; Eric P van der Veer; Carla M A van Alem; Ivo Que; Reshma A Lalai; Anton-Jan van Zonneveld; Joris I Rotmans; Paul H A Quax
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.